Notícias e Atividades da Galera Therapeutics

Galera Therapeutics é uma empresa listada sob o símbolo GRTX (US).

Fusão, aquisição e financiamento envolvendo Galera Therapeutics.

• Galera Therapeutics and Obsidian Therapeutics have announced they will merge  (publicado em 15 de abril de 2026)..

Veja o organograma con seus 6 executivos principais

Biografias mais buscadas da Galera Therapeutics

• Mel Sorensen, Director, President and Chief Executive Officer
• Kevin Lokay, Director
• Nancy Chang, Director

Recentes movimentos de executivos em Galera Therapeutics

• Jennifer Evans Stacey, Chief Legal and Compliance Officer, deixou a Companhia  (Notícia publicada em 8 de abril de 2026).

Criar um alerta
para seguir os movimentos de executivos da Galera Therapeutics.

Galera Therapeutics possui 2.406 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• Oak Hill Bio acaba de anunciar uma arrecadação de fundos de 33 milhões de dólares. (publicado em 4 de junho de 2026).
• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Galera Therapeutics

• Galera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic Cancer | Galera Therapeutics
• Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19 | Galera Therapeutics
• Galera Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit | Galera Therapeutics
• Galera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Placebo-Controlled Phase 1b/2a Clinical Trial of GC4419 in Combination with SBRT for Locally Advanced Pancreatic Cancer | Galera Thera
• Galera Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates | Galera Therapeutics
• News Releases | Galera Therapeutics
• Galera Therapeutics to Participate in Fireside Chat at 2020 BTIG Virtual Biotechnology Conference | Galera Therapeutics
• Galera Therapeutics Completes Enrollment of Phase 1b/2a Clinical Trial of GC4419 in Combination with Radiotherapy for Locally Advanced Pancreatic Cancer | Galera Therapeutics
• Galera Therapeutics Announces Avasopasem Manganese Improved Markers of Chronic Kidney Disease in Patients Receiving Cisplatin | Galera Therapeutics
• Galera Therapeutics to Host Virtual KOL Event on Cisplatin-Induced Chronic Kidney Disease | Galera Therapeutics
• View more press releases Close

Redes sociais sobre Galera Therapeutics

• Galera Therapeutics na Wikipedia, Google News e Yahoo Finance
• Galera Therapeutics na LinkedIn, X (Twitter) e YouTube